Pluri’s patent enables mass-scale production of immune cell therapies New patented technology is applicable for the expansion of a variety of immune cells Technology sets stage for potential immune cell therapy advancements and targets an estimated total addressable market of $11.66 billion by 2030 HAIFA, Israel, April 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company, Pluri Inc . (Nasdaq:PLUR) (TASE:PLUR) (“Pluri”... Read More